Stereotactic Intracerebral Injection of Allogenic IPSC-DAPs in Patients With Parkinson's Disease

General Information

Clinical trials phase Phase 1
Start date (estimated) 2025-11-15
End date (estimated) 2025-11-15
Clinical feature
Label Parkinson's disease
Link http://purl.obolibrary.org/obo/DOID_14330
Description A synucleinopathy that has_material_basis_in degeneration of the central nervous system that often impairs motor skills, speech, and other functions.; Xref MGI. OMIM mapping confirmed by DO. [SN].

Administrative Information

NCT number NCT07212088
ICTRP weblink https://trialsearch.who.int/Trial2.aspx?TrialID=NCT07212088
Source weblink https://clinicaltrials.gov/study/NCT07212088
Sponsors Second Affiliated Hospital Zhejiang University School of Medicine

Cells

Which differentiated cell type is used
Label dopaminergic neuron
Link http://purl.obolibrary.org/obo/CL_0000700
Description A neuron that releases dopamine as a neurotransmitter.

Recruitment

Recruitment Status Not yet recruiting
Estimated number of participants 12